GermanyGermany

RNAi screen yields flu targets

01.02.2010

Berlin – Whether pandemic or seasonal, no flu virus can replicate without hijacking various human genes. So why not target flu drugs to affect host genes, thereby minimising the risk that a virus could acquire resistance? Using gene-silencing methods (more...), German researchers have now screened for such human target genes. Headed by Thomas Meyer from the Berlin-based Max Planck Institute for Infection Biology, the team knocked down each of 287 candidate human genes in lung cell cultures before infecting them with N1N1, H1N5 and other flu viruses (Nature, doi:10.1038/nature08760). The results of the systematic RNAi screen suggest that some targets may have broad-spectrum therapeutic potential against multiple influenza strains. Inhibition of the cdc kinase with a small molecule compound for example reduced influenza virus replication by more than two orders of magnitude.

Germany, FranceGermany

21.12.2011

Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...

GermanyGermany

20.12.2011

Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...

GermanyGermany

16.12.2011

Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...

GermanyGermany

15.12.2011

Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...

GermanyGermany

15.12.2011

While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...

GermanyGermany

08.12.2011

Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...

GermanyGermany

03.11.2011

Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....

GermanyGermany

02.11.2011

Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/1/article/rnai-screen-yields-flu-targets.html

Product of the week

Products

Events

All Events

Current issue

All issues